Abstract
Chemotherapy-induced thrombocytopenia (CIT) is a critical complication that often necessitates dose reductions or treatment delays. This systematic review and network meta-analysis (NMA) of 16 randomized controlled trials (RCTs) evaluates the comparative efficacy and safety of various thrombopoietic agents. The findings identify eltrombopag as the most effective for maintaining chemotherapy schedules and avatrombopag as the safest option with the fewest adverse events.
Introduction: The Challenge of CIT
Chemotherapy-induced thrombocytopenia—a significant drop in platelet counts—poses a major hurdle in oncology. Beyond the immediate risk of internal bleeding, CIT frequently forces clinicians to delay subsequent chemotherapy cycles or reduce dosages. Such interruptions can compromise the relative dose intensity (RDI), potentially diminishing the overall survival of cancer patients.
While several treatment options are available, including recombinant human thrombopoietin (rhTPO), interleukin-11 (rhIL-11), and thrombopoietin receptor agonists (TPO-RAs) like eltrombopag and avatrombopag, there is a notable absence of head-to-head clinical trials. This lack of direct comparison leaves a gap in clinical guidelines regarding the optimal choice for balancing efficacy and safety.
Methodology
The researchers conducted a systematic review and NMA following the PRISMA guidelines. The study synthesized data from 16 RCTs involving 1,746 patients across various cancers, harvested from major medical databases with a search cutoff of July 2, 2024.
The Network Meta-Analysis Approach
Unlike traditional meta-analyses that only compare a drug against a placebo, an NMA utilizes mathematical modeling to perform indirect comparisons. For instance, if Drug A and Drug B have both been compared to a placebo in separate trials, the NMA can estimate the relative efficacy of Drug A versus Drug B.
Treatments were ranked using SUCRA (Surface Under the Cumulative Ranking curve) scores, where a score closer to 1 indicates a higher probability of being the most effective or safest treatment for a given outcome.
Key Insights and Results
The analysis revealed distinct leaders in efficacy and safety:
- Efficacy Leader (Eltrombopag): Eltrombopag ranked highest for maintaining chemotherapy schedules. It was the most effective at reducing dose reductions or delays and increasing the platelet count "nadir" (the lowest point during a cycle).
- Safety Leader (Avatrombopag): Avatrombopag demonstrated the most favorable safety profile, with the lowest incidence of adverse events and thromboembolism. It also showed promise in supporting the recovery of hemoglobin and neutrophil levels.
- Interleukin-based Treatments: While rhIL-11 was effective at reducing the need for platelet transfusions, it was associated with the highest risk of adverse events, including arrhythmias and fluid retention. rhTPO was highly effective at preventing severe (Grade 3/4) thrombocytopenia.
Overall, the TPO-RA class (eltrombopag, avatrombopag, romiplostim) showed superior tolerability and efficacy compared to older interleukin-based therapies. Specifically, TPO-RAs reduced chemotherapy delays or dose reductions by 63% compared to placebo (OR = 0.37) and halved the incidence of severe thrombocytopenia (OR = 0.50).
Limitations and Future Directions
The study identifies several limitations that suggest caution:
- Sample Size: Some agents, such as avatrombopag, were represented by limited data (single studies).
- Risk of Bias: Several trials had "unclear" randomization details, leading to potential bias.
- Heterogeneity: Varying definitions of outcomes like "bleeding events" across studies made direct comparisons challenging.
Future research should focus on large-scale, multicenter head-to-head RCTs, particularly comparing newer TPO-RAs like avatrombopag against established treatments to refine clinical decision-making.
Summary updated